Hebei Tongchuang Pharmaceutical Co., Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation sodium valproate extended-release tablets (I) (specification: 0.5 g, produced by Yiling Wanzhou International Pharmaceutical Co., Ltd.) and the reference preparation sodium valproate extended-release tablets (I) (Depakin®, specification: 0.5 g, produced by Sanofi (Hangzhou) Pharmaceutical Co., Ltd.) in healthy participants after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation sodium valproate extended-release tablets (I) (specification: 0.5 g) and the reference preparation sodium valproate extended-release tablets (I) (Depakin®, specification: 0.5 g) in healthy participants.